EMA: Draft asenapine sublingual tablets 5 and 10 mg product-specific bioequivalence guidance

The European Medicines Agency has decided to routinely publish product-specific bioequivalence guidance for a more consistent approach to the assessment of marketing authorisation applications for generic medicines across all authorisation routes available in the European Union. This guidance document describes the specific requirements for the demonstration of bioequivalence for asenapine sublingual.